Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS
Jerusalem (ots/PRNewswire) -
* Results from phase 2a trial in ALS patients were published in Muscle and Nerve.
* Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the!-->…
Weiterlesen...
Weiterlesen...